DisperSol Technologies Announces New R&D Data to Be Presented at 2017 Annual Meeting of AAPS  

GEORGETOWN, Texas--(BUSINESS WIRE)-- DisperSol Technologies, a clinical stage pharmaceutical company developing a product pipeline of reformulated poorly water-soluble drugs, announced today that it will be hosting a technology symposium entitled “Enhanced Amorphous Solid Dispersions with KinetiSol^®: Industry Case Studies” at 9:00 a.m. on Tuesday, November 14, 2017 in San Diego during the Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS). The symposium will highlight partners' experiences with KinetiSol^®: a novel manufacturing technology for making amorphous solid dispersions of poorly water-soluble drug molecules to enhance their bioavailability & clinical effectiveness. Here, for the first time in a public forum, partners will present case studies on the application of KinetiSol^® technology to their internal product development programs. Includes presentations by: Keith Horspool, PhD, Boehringer Ingelheim; James Wesley, PhD, Eli Lilly; Professor Bill Williams, PhD, University of Texas.

Dave Miller, Vice President of Research & Development at DisperSol Technologies, is leading the symposium and will also be presenting. Additionally, Dr. Miller will be presenting the latest data on enhanced KinetiSol formulations of approved drugs as compared to the original marketed commercial formulations in a symposium on Monday, November 13, 2017 hosted by Shin-Etsu Chemical Company, a leading supplier of polymer excipients for amorphous solid dispersion applications.

About DisperSol

DisperSol is an innovator in the formulation development and manufacture of pharmaceutical drugs. DisperSol’s KinetiSol^® technology has dramatically improved the effectiveness of drugs by superior enhancement of drug loading, solubility, permeability and bioavailability relative to other technologies. This has enabled the improvement of approved drugs and the successful formulation of new drugs of significant clinical promise that would otherwise have no development path forward to patients. KinetiSol^® is a patent protected manufacturing method that is efficient, cost-effective and can generate new market exclusivity for its enhanced formulations of even off-patent drug products.

DisperSol commercializes the KinetiSol^® platform through a combination of external partnerships and internal drug development programs. For more information, visit www.dispersoltech.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171108006633/en/